Cargando…

Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report

RATIONALE: The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy. PATIENT CONCERNS: A 48-year-old Caucasian man presented to our department in...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Raoul Kanav, Hage, Rabih, Hage, Alexandre, Polin, Vanessa, Sené, Thomas, Vignal-Clermont, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310519/
https://www.ncbi.nlm.nih.gov/pubmed/30544405
http://dx.doi.org/10.1097/MD.0000000000013365
_version_ 1783383451276148736
author Khanna, Raoul Kanav
Hage, Rabih
Hage, Alexandre
Polin, Vanessa
Sené, Thomas
Vignal-Clermont, Catherine
author_facet Khanna, Raoul Kanav
Hage, Rabih
Hage, Alexandre
Polin, Vanessa
Sené, Thomas
Vignal-Clermont, Catherine
author_sort Khanna, Raoul Kanav
collection PubMed
description RATIONALE: The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy. PATIENT CONCERNS: A 48-year-old Caucasian man presented to our department in June 2016 for decreased vision, transient visual obscuration, pulsatile tinnitus and headaches of 7 months duration. Bilateral optic disc swelling was found at fundus examination. Brain MRI excluded any brain tumor and lumbar puncture showed cerebrospinal fluid (CSF) opening pressure of 26 cm of water with normal CSF contents. DIAGNOSES: Idiopathic ICH was suspected. INTERVENTIONS: The patient was managed with oral acetazolamide. Headaches initially improved but the dosage could not be decreased under 750 mg a day without recurrence of the symptoms. Extensive review of systems showed that the patient had active UC. He was given oral mesalazine, 2000 mg a day. OUTCOMES: The symptoms of UC and ICH quickly resolved. Acetazolamide was progressively tapered over the course of the 9 subsequent months and the patient did not show any worsening of his symptoms or papilledema. LESSONS: UC should be added to the list of disorders associated with ICH. In case of atypical ICH with drug dependency, investigations should seek for UC. Treating efficiently UC with mesalazine may improve ICH, suggesting an underlying inflammatory process.
format Online
Article
Text
id pubmed-6310519
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63105192019-01-14 Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report Khanna, Raoul Kanav Hage, Rabih Hage, Alexandre Polin, Vanessa Sené, Thomas Vignal-Clermont, Catherine Medicine (Baltimore) Research Article RATIONALE: The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy. PATIENT CONCERNS: A 48-year-old Caucasian man presented to our department in June 2016 for decreased vision, transient visual obscuration, pulsatile tinnitus and headaches of 7 months duration. Bilateral optic disc swelling was found at fundus examination. Brain MRI excluded any brain tumor and lumbar puncture showed cerebrospinal fluid (CSF) opening pressure of 26 cm of water with normal CSF contents. DIAGNOSES: Idiopathic ICH was suspected. INTERVENTIONS: The patient was managed with oral acetazolamide. Headaches initially improved but the dosage could not be decreased under 750 mg a day without recurrence of the symptoms. Extensive review of systems showed that the patient had active UC. He was given oral mesalazine, 2000 mg a day. OUTCOMES: The symptoms of UC and ICH quickly resolved. Acetazolamide was progressively tapered over the course of the 9 subsequent months and the patient did not show any worsening of his symptoms or papilledema. LESSONS: UC should be added to the list of disorders associated with ICH. In case of atypical ICH with drug dependency, investigations should seek for UC. Treating efficiently UC with mesalazine may improve ICH, suggesting an underlying inflammatory process. Wolters Kluwer Health 2018-12-10 /pmc/articles/PMC6310519/ /pubmed/30544405 http://dx.doi.org/10.1097/MD.0000000000013365 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Khanna, Raoul Kanav
Hage, Rabih
Hage, Alexandre
Polin, Vanessa
Sené, Thomas
Vignal-Clermont, Catherine
Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
title Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
title_full Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
title_fullStr Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
title_full_unstemmed Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
title_short Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report
title_sort mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310519/
https://www.ncbi.nlm.nih.gov/pubmed/30544405
http://dx.doi.org/10.1097/MD.0000000000013365
work_keys_str_mv AT khannaraoulkanav mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport
AT hagerabih mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport
AT hagealexandre mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport
AT polinvanessa mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport
AT senethomas mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport
AT vignalclermontcatherine mesalazinetreatmentcausingresolutionofintracranialhypertensionsecondarytoulcerativecolitisacasereport